Genomic Alterations as Inclusion Criteria in Oncology Trials
Genomic Alterations as Inclusion Criteria in Oncology Trials Designing Oncology Trials That Use Genomic Alterations for Eligibility Why use genomic alterations as inclusion criteria—and when? Genomic inclusion criteria align the investigational therapy’s mechanism of action with patients most likely to benefit. Instead of enrolling “all‑comers,” you prospectively select participants with actionable alterations—EGFR exon 19 deletions,…
Read More “Genomic Alterations as Inclusion Criteria in Oncology Trials” »